Belli O, Karava K, Farouni R, Platt R
Nat Biotechnol. 2024; .
PMID: 39533106
DOI: 10.1038/s41587-024-02439-1.
Zhang Z, Gao Z, He J, Ma C, Tao H, Zhu F
Br J Cancer. 2024; 131(8):1387-1398.
PMID: 39266624
PMC: 11473956.
DOI: 10.1038/s41416-024-02842-0.
Detchou D, Barrie U
Neurosurg Rev. 2024; 47(1):448.
PMID: 39164434
DOI: 10.1007/s10143-024-02695-4.
Bagchi A, Stayrook S, Xenaki K, Starbird C, Doulkeridou S, El Khoulati R
Structure. 2024; 32(9):1367-1380.e6.
PMID: 38908376
PMC: 11380598.
DOI: 10.1016/j.str.2024.05.018.
Richard S
Open Med (Wars). 2024; 19(1):20240981.
PMID: 38868315
PMC: 11167713.
DOI: 10.1515/med-2024-0981.
Non-Tumor Cells within the Tumor Microenvironment-The "Eminence Grise" of the Glioblastoma Pathogenesis and Potential Targets for Therapy.
Bugakova A, Chudakova D, Myzina M, Yanysheva E, Ozerskaya I, Soboleva A
Cells. 2024; 13(10.
PMID: 38786032
PMC: 11119139.
DOI: 10.3390/cells13100808.
Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma.
Seo K, Hwang K, Nam K, Kim M, Song Y, Kim C
Pharmaceutics. 2024; 16(4).
PMID: 38675227
PMC: 11055028.
DOI: 10.3390/pharmaceutics16040566.
CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle.
Zhou H, Wang Y, Wang T, Wu W, Cao Y, Zhang B
Oncol Lett. 2024; 27(5):206.
PMID: 38516683
PMC: 10956385.
DOI: 10.3892/ol.2024.14339.
EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors.
Gross F, Mancini A, Breton B, Kobayashi H, Pereira P, Le Gouill C
Commun Biol. 2024; 7(1):250.
PMID: 38429428
PMC: 10907714.
DOI: 10.1038/s42003-024-05965-5.
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S, Salib S, Balasubramaniam M, Aboud O
Int J Mol Sci. 2024; 25(4).
PMID: 38396993
PMC: 10889328.
DOI: 10.3390/ijms25042316.
Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma.
Mahmoudi K, Kim D, Tavakkol E, Kihira S, Bauer A, Tsankova N
Cancers (Basel). 2024; 16(3).
PMID: 38339340
PMC: 10854536.
DOI: 10.3390/cancers16030589.
Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions.
Moeinafshar A, Nouri M, Shokrollahi N, Masrour M, Behnam A, Tehrani Fateh S
Cancer Cell Int. 2024; 24(1):26.
PMID: 38200584
PMC: 10782702.
DOI: 10.1186/s12935-023-03203-2.
Role of Glycolytic and Glutamine Metabolism Reprogramming on the Proliferation, Invasion, and Apoptosis Resistance through Modulation of Signaling Pathways in Glioblastoma.
Trejo-Solis C, Silva-Adaya D, Serrano-Garcia N, Magana-Maldonado R, Jimenez-Farfan D, Ferreira-Guerrero E
Int J Mol Sci. 2023; 24(24).
PMID: 38139462
PMC: 10744281.
DOI: 10.3390/ijms242417633.
EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
Lv D, Zhong C, Dixit D, Yang K, Wu Q, Godugu B
Mol Cell. 2023; 83(23):4334-4351.e7.
PMID: 37979586
PMC: 10842222.
DOI: 10.1016/j.molcel.2023.10.025.
EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma.
Martija A, Krauss A, Bachle N, Doth L, Christians A, Krunic D
Acta Neuropathol Commun. 2023; 11(1):177.
PMID: 37936247
PMC: 10629159.
DOI: 10.1186/s40478-023-01673-z.
Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases.
Merati A, Kotian S, Acton A, Placzek W, Smithberger E, Shelton A
Int J Mol Sci. 2023; 24(18).
PMID: 37761989
PMC: 10530722.
DOI: 10.3390/ijms241813688.
Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review.
Nahar Metu C, Sutihar S, Sohel M, Zohora F, Hasan A, Miah M
Cancer Rep (Hoboken). 2023; 6(10):e1889.
PMID: 37675821
PMC: 10598261.
DOI: 10.1002/cnr2.1889.
A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.
Huang W, Li J, Zhu H, Qin X, Chen C, Wang B
Neuro Oncol. 2023; 26(1):85-99.
PMID: 37616578
PMC: 10768976.
DOI: 10.1093/neuonc/noad153.
Macrophage's role in solid tumors: two edges of a sword.
Jahandideh A, Yarizadeh M, Masjedi M, Fatehnejad M, Jahandideh R, Soheili R
Cancer Cell Int. 2023; 23(1):150.
PMID: 37525217
PMC: 10391843.
DOI: 10.1186/s12935-023-02999-3.
Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.
Bailleul J, Vlashi E
Antioxid Redox Signal. 2023; 39(13-15):957-979.
PMID: 37022791
PMC: 10655009.
DOI: 10.1089/ars.2022.0088.